NLSUI OPAC header image

Impact of Patent Law on Regulations Facilitating Access to Medicine: (Record no. 114583)

MARC details
000 -LEADER
fixed length control field 05005nam a2200229Ia 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20251126121852.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201217b2018 ||||| |||| 00| 0 eng
040 ## - CATALOGING SOURCE
Transcribing agency nls
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Gangwal Nishid Ashokkumar
245 #0 - TITLE STATEMENT
Title Impact of Patent Law on Regulations Facilitating Access to Medicine:
Remainder of title A Comparative Study
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Bangalore
Name of publisher, distributor, etc. NLSIU
Date of publication, distribution, etc. 2018
300 ## - PHYSICAL DESCRIPTION
Extent 353p
505 ## - FORMATTED CONTENTS NOTE
Formatted contents note Table of Content<br/>List of Abbreviations;<br/>List of Tables;<br/>List of Figures;<br/>List of Cases;<br/>List of Annexure;<br/>CHAPTER - 1 Introduction and Research Methodology;<br/>1.1 Introduction;<br/>1.2 Statement of Problem and Research Significance;<br/>1.3 Research Questions;<br/>1.4 Research Hypotheses;<br/>1.5 Research Methodology;<br/>Tables;<br/>CHAPTER - 2 Patents - A Tool for Progress of Scientific Innovations as well as for Competition;<br/>2.1 Introduction;<br/>2.2 Historical Development of Patents;<br/>2.3 Development of Intellectual Law in India;<br/>2.4 Globalization of Patent Laws;<br/>2.5 Innovation activity and Pharmaceutical Industry;<br/>2.6 Conclusions;<br/>Tables;<br/>CHAPTER-3 Patent Systems and the Business Policies of the Pharmaceutical Companies;<br/>3.1 Introduction;<br/>Offensive Business Strategies;<br/>Defensive Business Strategies;<br/>3.2 Patent Cluster's or thickets;<br/>3.3 Introduction of New formulation;<br/>3.4 Chiral Switches;<br/>3.5 Aggressive Enforcement of Patent Rights;<br/>3.6 Pseudo-generics;<br/>3.7 Differential pricing mechanism;<br/>3.8 Licensing and cross licensing;<br/>3.9 Multiple / collaborative research;<br/>a WIPO Re:Search - Sharing Innovation in the Fight Against Neglected Tropical Diseases;<br/>b Drugs for Neglected Diseases Initiative – A Patient Needs-Driven & Innovative R&D Model;<br/>c African Network for Drugs and Diagnostic Innovation (ANDI);<br/>d Meningitis Vaccine Project;<br/>e Open Source Drug Discovery of CSIR;<br/>3.10 Conclusions;<br/>Tables;<br/>CHAPTER -4 Differential Pricing Policy and Pharmaceutical Industry;<br/>4.1 Introduction;<br/>4.2 Theory of Differential Pricing;<br/>4.2a The methodology of Drug Pricing;<br/>Ramsey Pricing Model;<br/>Value based Pricing Model;<br/>Two Part Pricing Model;<br/>Patent Buyout Pricing Model;<br/>Peak Load Pricing Model;<br/>4.3 Differential Pricing and Pharmaceutical Industry a The pharmaceutical manufacturer sells the same product for different prices;<br/>b Opening New Market;<br/>c Threat of Compulsory Licensing;<br/>d Competition From Generic Producers;<br/>4.4 Prerequisite for Pharmaceutical manufacturer to implement the differential pricing;<br/>4.5 Factors That Impede Use of Differential Pricing a Discontent With Prices In the Middle-Income Tier;<br/>b Lack of Market Segmentation;<br/>c Inefficient and 'Black-Box' Distribution Systems;<br/>4.6 The Current State of Differential Pricing;<br/>4.7 Conclusions;<br/>Tables;<br/>CHAPTER -5 TRIPS flexibilities - A Solution to Address the Need and Demand of Medicine;<br/>5.1 Introduction;<br/>5.2 Compulsory Licensing a Review of Compulsory Licensing System;<br/>Australia;<br/>Argentina;<br/>Brazil;<br/>Canada;<br/>China;<br/>India;<br/>Indonesia;<br/>USA;<br/>b Potential dangers arising from Compulsory Licensing;<br/>5.3 Parallel Imports and Exhaustion of Rights;<br/>5.4 Patentable subject matter: Limitation on the Grant of Patents;<br/>a) Non-patentable subject matter Use of Pharmaceutical Substances Incremental innovation (new form of existing drugs);<br/>b) Other Conflicting Areas of Patentability: Scope for Proper Application of Patentability Standards;<br/>Generic and specific patents (selection Patent and double Patenting);<br/>Patents having claims related to Pharmacokinetic parameters;<br/>Patents claiming pharmacopeial/analytical methods;<br/>Packaging Method Patents;<br/>5.5 Research and the Early Working Exceptions;<br/>European Countries;<br/>America;<br/>Australia and New Zealand;<br/>India;<br/>Other Countries;<br/>5.6 TRIPS-PLUS" IN US Free Trade Agreements;<br/>a) Limiting the Extent of Test Data Protection (Data Exclusivity);<br/>b) Patent Term Extensions;<br/>c) Patent Linkage;<br/>USA;<br/>Canada;<br/>South Korea;<br/>Mexico;<br/>Singapore;<br/>Australia;<br/>Europe;<br/>India;<br/>5.7 Conclusions;<br/>5.8 Tables;<br/>CHAPTER· 6 Health Policy and Pricing Systems: Global Scenario;<br/>6.1 Introduction;<br/>6.2 United States of America;<br/>6.3 Canada;<br/>6.4 Australia;<br/>6.5 China;<br/>6.6 Europe;<br/>Germany;<br/>Italy;<br/>Spain;<br/>France;<br/>United Kingdom;<br/>6.7 India;<br/>6.8 Conclusions;<br/>Tables;<br/>CHAPTER- 7 Conclusions and Recommendations;<br/>7.1 Conclusions;<br/>7.2 Recommendations;<br/>Guidelines to ensure for proper application for standard of Patentability;<br/>Two tier examination mechanism for Pharmaceutical patents;<br/>Proper application of "Utility" standard for Pharmaceutical Patents;<br/>Changes in the Health / Regulatory System;<br/>Patent linkage;<br/>Data exclusivity;<br/>Patent Term Extensions;<br/>Drug Pricing Policy;<br/>Need for Health Insurance;<br/>Bibliography.<br/>
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Patent System & Business Policies - Pharmaceutical companies
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pricing policy & Pharmaceuticl Industry
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
General subdivision Thesis
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Geographic subdivision TRIPS
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prof.(Dr.) T Ramakrishna (Guide)
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://dans.nls.ac.in/handle/123456789/369">https://dans.nls.ac.in/handle/123456789/369</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Thesis
Source of classification or shelving scheme Dewey Decimal Classification
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     . .   08.08.2019   PhD077 08.08.2019 08.08.2019 Thesis